|1.||Rattan, Ashok: 3 articles (01/2013 - 10/2004)|
|2.||Mathur, Tarun: 3 articles (01/2013 - 10/2004)|
|3.||Singhal, Smita: 2 articles (01/2013 - 12/2005)|
|4.||Upadhyay, Dilip J: 2 articles (01/2013 - 04/2008)|
|5.||Barman, Tarani Kanta: 2 articles (01/2013 - 04/2008)|
|6.||Khan, Seema: 2 articles (01/2013 - 12/2005)|
|7.||Fatma, Tasneem: 2 articles (12/2005 - 10/2004)|
|8.||Raj, V Samuel: 1 article (01/2013)|
|9.||Kalia, Vandana: 1 article (01/2013)|
|10.||Pandya, M: 1 article (08/2008)|
08/01/2008 - "This study indicates that RBx 7644 has anti-adhesion potential and may emerge as an important antibiotic for prevention and treatment of device-related infections caused by staphylococci."
10/01/2004 - "In conclusion, this study indicated that ranbezolid had potent activity against adherent staphylococci isolates and may prove useful in the prevention and treatment of device related infections caused by staphylococci."
01/01/2013 - "Ranbezolid showed 5.39log(10) reduction and linezolid showed 1.15log(10) reduction in murine disk implant infection with B. "
12/01/2005 - "The present study thus indicated that slime interferes with the antimicrobial effect of glycopeptide drugs (vancomycin, teicoplanin), and that for effective prevention and treatment of prosthetic device-related infections, appropriate and newer antibiotics such as ranbezolid should be considered."
02/01/2007 - "Daptomycin, dalbavancin, oritavancin, telavancin, iclaprim and ranbezolid seem to be promising agents against infections caused by Gram-positive pathogens and effectively address the present problems of multi-resistance in Gram-positive infections. "
|2.||Body Weight (Weight, Body)
|3.||Anti-Bacterial Agents (Antibiotics)
|8.||iclaprim (AR 100)